Filing Details

Accession Number:
0000899243-19-028027
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-11-22 21:00:22
Reporting Period:
2019-11-21
Accepted Time:
2019-11-22 21:00:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1731831 Eidos Therapeutics Inc. EIDX Pharmaceutical Preparations (2834) 463733671
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1743029 Christine Siu C/O Eidos Therapeutics, Inc.
101 Montgomery Street, Suite 2000
San Francisco CA 94104
Cfo And Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-11-21 25,000 $0.59 61,470 No 4 M Direct
Common Stock Disposition 2019-11-21 24,800 $55.12 36,670 No 4 S Direct
Common Stock Disposition 2019-11-21 200 $56.00 36,470 No 4 S Direct
Common Stock Acquisiton 2019-11-22 10,000 $0.59 46,470 No 4 M Direct
Common Stock Disposition 2019-11-22 9,399 $54.71 37,071 No 4 S Direct
Common Stock Disposition 2019-11-22 601 $55.29 36,470 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2019-11-21 25,000 $0.00 25,000 $0.59
Common Stock Stock Option (right to buy) Disposition 2019-11-21 10,000 $0.00 10,000 $0.59
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
192,191 2027-12-21 No 4 M Direct
182,191 2027-12-21 No 4 M Direct
Footnotes
  1. Represents the weighted average sale price of the shares sold from $55.00 to $55.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  2. Represents the weighted average sale price of the shares sold from $54.21 to $55.19 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  3. Represents the weighted average sale price of the shares sold from $55.21 to $55.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  4. The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.